REMEGEN
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2008-07-04
- Employees
- 3.4K
- Market Cap
- -
- Website
- http://www.remegen.com
- Introduction
The company was co-founded in 2008 by Yantai Rongchang Pharmaceutical Co., Ltd., headed by Mr. Wang Weidong, and American scientist Dr. Fang Jianmin. The company is committed to discovering, developing, producing and commercializing first-of-its-kind, best-in-class biopharmaceuticals, and creating a number of new biological drugs with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. The company is an innovative biopharmaceutical company with a global perspective. Since its establishment, it has been focusing on therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and double antibodies. Main products: tetacip, vidicetumab, RC28, RC88, RC98, RC108, RC118, RC148, RC198, etc.
RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects
- Conditions
- NMIBC
- Interventions
- Drug: RC48-ADC in Combination with gemcitabine
- First Posted Date
- 2023-07-13
- Last Posted Date
- 2023-07-13
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05943379
- Locations
- 🇨🇳
Peking University First Hosptital, Beijing, Beijing, China
RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression
- First Posted Date
- 2023-07-11
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05940896
- Locations
- 🇨🇳
Shandong Cancer hospital &Institute, Jinan, Shandong, China
Efficacy and Safety of RC28-E Versus Aflibercept in Diabetic Macular Edema
- Conditions
- Diabetic Macular Edema
- Interventions
- Biological: RC-28EBiological: Aflibercept
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-09-05
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT05885503
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
A RC198 Study in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
- Conditions
- Renal Cell CarcinomaNon-small Cell Lung CancerHead and Neck Squamous Cell CarcinomaMelanomaUrothelial CarcinomaColorectal Carcinoma
- Interventions
- Drug: RC198 Injection
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT05867303
- Locations
- 🇦🇺
ICON Cancer Centre Wesley, Auchenflower, Queensland, Australia
🇦🇺Southern Oncology Clinical Research Unit, Bedford Park, South Australia, Australia
🇦🇺Cabrini Hospital Malvern, Malvern, Victoria, Australia
RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC
- First Posted Date
- 2023-04-20
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 106
- Registration Number
- NCT05821933
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-04-30
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 82
- Registration Number
- NCT05804526
- Locations
- 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
A Study of Telitacicept in Patients With Primary IgA Nephropathy
- Conditions
- Primary IgA Nephropathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 308
- Registration Number
- NCT05799287
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei, Anhui, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 26
- Registration Number
- NCT05745740
- Locations
- 🇨🇳
Shanghai Pulmonary Hospital, Shanghai, Shanghai, China
Study of Telitacicept in Generalized Myasthenia Gravis
- Conditions
- Myasthenia Gravis, Generalized
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 114
- Registration Number
- NCT05737160
- Locations
- 🇨🇳
The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Beijing Hospital, Beijing, Beijing, China
Efficacy and Safety of RC28-E Versus Aflibercept
- Conditions
- Wet Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2023-02-14
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- RemeGen Co., Ltd.
- Target Recruit Count
- 432
- Registration Number
- NCT05727397
- Locations
- 🇨🇳
Beijing Hospital, Beijing, Beijing, China